At the Forefront of Global Radiolabeled Drug Development: Wuxi Beita Pharmatech Invited to the International Isotope Society North American Chapter Annual Meeting, Its Research Widely Acclaimed
Release time:
2026-11-12
Wuxi Beita Pharmatech (Beita) was invited to the annual meeting of the North American Chapter of the International Isotope Society (IIS), where it presented three papers on carbon-14 labeling and hosted a dedicated exhibition booth showcasing its core technologies and product solutions in isotope labeling. It was the only Chinese company among the ten isotope-labeling vendors exhibiting at the meeting.

The meeting was held on October 5–6, 2026, in Morristown, New Jersey, and is one of the most influential international conferences in the isotope field. It brought together global pharmaceutical leaders — including Johnson & Johnson, Merck, Bristol Myers Squibb, Eli Lilly, AstraZeneca, Boehringer Ingelheim, Vertex and Corteva Agriscience — alongside a number of specialist isotope-labeling service providers. Scholars from leading U.S. universities delivered keynote lectures, and radiochemistry R&D teams from more than ten pharmaceutical companies shared their latest progress in radioisotope labeling and synthesis.
Dr. Yinsheng Zhang, Vice President of Beita and a member of the BOT of the International Isotope Society, attended and presented on the company's behalf. Beita reported three carbon-14 labeling studies:
- Design and Synthesis of the C-14 Labeled Anticancer Drug Fovinaciclib Citrate
- Design and Synthesis of the C-14 Labeled Herbicide Glufosinate-P
- Improved Synthesis of [¹⁴C]TRX-818, an Anticancer Drug Candidate



The meeting gave the team valuable opportunities for in-depth, face-to-face exchanges with radiochemistry leads at multinational pharmaceutical companies. Beita's isotope-labeling capability, product quality and one-stop service offering were well received by industry peers.
Previous
Related News